The clearance, granted via a traditional 510(k) pathway, designates the devices as substantially equivalent for their intended use.
ICU Medical has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its NORMOFLO Irrigation Fluid Warming Sets and Accessories. The clearance, identified as K262532, was decided on September 18, 2026, marking the agency's determination of substantial equivalence for the devices.
The NORMOFLO system, comprising models IR-601, IR-501, IR-61, and PL-61, falls under the product code LGZ and regulation number 880.5725. This classification places the devices as Class II medical devices, typically subject to general and special controls to ensure safety and effectiveness. The Traditional 510(k) submission required ICU Medical to demonstrate that the new devices are at least as safe and effective as a legally marketed predicate device.
Device Specifics and Regulatory Pathway
The FDA's decision indicates that the NORMOFLO Irrigation Fluid Warming Sets and Accessories are deemed substantially equivalent to a predicate device, meaning they have the same intended use and technological characteristics as a device already on the market, or if they differ, the differences do not raise new questions of safety or effectiveness. The clearance process for these devices was a Traditional 510(k), which is typically used for novel devices that are not significantly different from existing ones.
The advisory committee consulted for this clearance was the General Hospital panel, which reviews a broad range of general medical and surgical devices. The FDA clearance was issued based on a publicly available summary statement rather than a full safety and effectiveness declaration, standard for 510(k) submissions.
Market Implications and Future Outlook
While the 510(k) clearance allows ICU Medical to market these specific NORMOFLO products in the U.S., the company has not yet disclosed specifics regarding commercial launch timelines, pricing, or the expected impact on its financial outlook. The irrigation fluid warming sets address a segment of the medical device market focused on patient temperature management during various clinical procedures where warmed fluids are administered.
The substantial equivalence determination is a critical regulatory milestone, enabling market entry without requiring the more extensive clinical trial data associated with Premarket Approval (PMA) applications.
Further details concerning the specific clinical applications or comparative performance data against existing warming solutions are not immediately available from the regulatory filing. ProjMed will continue to monitor any subsequent company announcements or clinical data releases related to the NORMOFLO Irrigation Fluid Warming Sets and Accessories.
